(Total Views: 741)
Posted On: 06/29/2020 1:56:22 AM
Post# of 145250
There does seem to be some selective blocking going on. We just don't know what kind which is why I bemoan the fact there is so little basic research on leronlimab. Dr. Patterson's tests are sorting that out a bit.
But with GPCRs and chemokines there's a secondary pathway through either CCR1 or CCR3 receptors. There's less binding affinity and much fewer of those receptors. You will get an immune response absent CCR5 just a milder one. Of course with CCR5 delta 32 double allele gene deletion you still have a fairly strong response because CCR1, CCR3 and binding ramp up to take the place of CCR5.
But with GPCRs and chemokines there's a secondary pathway through either CCR1 or CCR3 receptors. There's less binding affinity and much fewer of those receptors. You will get an immune response absent CCR5 just a milder one. Of course with CCR5 delta 32 double allele gene deletion you still have a fairly strong response because CCR1, CCR3 and binding ramp up to take the place of CCR5.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)